Adenosine and autism: A spectrum of opportunities

Neuropharmacology

Volumn 68, Issue , 2013, Pages 116-121

  Masino, Susan A ^a   Kawamura Jr , Masahito ^b   Cote, Jessica L ^a   Williams, Rebecca B ^a   Ruskin, David N ^a  

^a TRINITY COLLEGE   (United States)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenosine; Anxiety; ATP; Autism; Ketogenic diet; Metabolism

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; CAFFEINE;

ACUTE DRUG ADMINISTRATION; ANXIETY; AUTISM; BEHAVIOR; CHRONIC DRUG ADMINISTRATION; DRUG TARGETING; EMOTIONAL DISORDER; EPILEPSY; HUMAN; KETOGENIC DIET; METABOLIC THERAPY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; REVIEW; SCHIZOPHRENIA; SEIZURE; SENSORY DYSFUNCTION; SYMPTOM; THERAPY;

ADENOSINE; ANIMALS; AUTISTIC DISORDER; HUMANS;

EID: 84875224060     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.08.013     Document Type: Review

References (106)

1. S. Akhondzadeh, M.R. Milajerdi, H. Amini, and M. Tehrani-Doost Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial Bipolar Disord. 8 2006 485 489
2. S. Akhondzadeh, E. Shasavand, H. Jamilian, O. Shabestari, and A. Kamalipour Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions J. Clin. Pharm. Ther. 25 2000 131 137
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders IV, Text Revision 2000 American Psychiatric Association Washington DC
4. J.A. Bartz, and E. Hollander Oxytocin and experimental therapeutics in autism spectrum disorders Prog. Brain Res. 170 2008 451 462
5. D.Q. Beversdorf The role of the noradrenergic system in autism spectrum disorders G.J. Blatt, Neurochemical Basis of Autism: from Molecules to Minicolumns 2010 Springer New York 175 184
6. 1 receptors J. Neurosci. 29 2009 1267 1276
7. D. Boison, S.A. Masino, and J.D. Geiger Homeostatic bioenergetic network regulation: a novel concept to avoid pharmacoresistance in epilepsy Expert Opin. Drug Discov. 6 2011 713 724
8. D. Boison, P. Singer, H.-Y. Shen, J. Feldon, and B.K. Yee Adenosine hypothesis of schizophrenia-opportunities for pharmacotherapy Neuropharmacology 62 2012 1527 1543
9. M.G. Brunstein, P. Belmonte-de-Abreu, D.O. Souza, and D.R. Lara Therapeutic benefit of adjunctive dipyridamole in schizophrenia is probably due to adenosine-glutamate interactions J. Clin. Pharm. Ther. 26 2001 155 156
10. J.K. Buitelaar, and S.H. Willemsen-Swinkels Medication treatment in subjects with autistic spectrum disorders Eur. Child Adolesc. Psychiatry 9 Suppl. 1 2000 85 97
11. G. Burnstock, U. Krügel, M.P. Abbracchio, and P. Illes Purinergic signalling: from normal behaviour to pathological brain function Prog. Neurobiol. 95 2011 229 274
12. Centers for Disease Control and Prevention Prevalence of autism spectrum disorders-autism and developmental disabilities monitoring network, 14 sites, United States, 2008 Morbidity Mortality Weekly Rep. 61 2012 1 19
13. G.Q. Chen, Y.Y. Chen, X.S. Wang, S.Z. Wu, H.M. Yang, H.Q. Xu, J.C. He, X.T. Wang, J.F. Chen, and R.Y. Zheng Chronic caffeine treatment attenuates experimental autoimmune encephalomyelitis induced by guinea pig spinal cord homogenates in Wistar rats Brain Res. 1309 2010 116 125
14. C. Cheung, K. Yu, G. Fung, M. Leung, C. Wong, Q. Li, P. Sham, S. Chua, and G. McAlonan Autistic disorders and schizophrenia: related or remote? An anatomical likelihood estimation PLoS One 5 2010 e12233
15. M. Connor Allopurinol for pain relief: more than just crystal clearance? Br. J. Pharmacol. 156 2009 4 6
16. S.P. Dahlgren, and C. Gillberg Symptoms in the first two years of life: a preliminary population study of infantile autism Eur. Arch. Psychiatry Neurol. Sci. 238 1989 169 174
17. P. DeMarco, and P. Zagnoni Allopurinol and severe epilepsy Neurology 36 1986 1538 1539
18. F.B. Dickerson, C.R. Stallings, A.E. Origoni, A. Sullens, S. Khushalani, N. Sandson, and R.H. Yolken A double-blind trial of adjunctive allopurinol for schizophrenia Schizophr. Res. 109 2009 66 69
19. T.V. Dunwiddie, and S.A. Masino The role and regulation of adenosine in the central nervous system Annu. Rev. Neurosci. 24 2001 31 55
20. L.A. Etherington, and B.G. Frenguelli Endogenous adenosine modulates epileptiform activity in rat hippocampus in a receptor subtype-dependent manner Eur. J. Neurosci. 19 2004 2539 2550
21. A. Evangeliou, I. Vlachonikolis, H. Mihailidou, M. Spilioti, A. Skarpalezou, N. Makaronas, A. Prokopiou, P. Christodoulou, G. Liapi-Adamidou, E. Helidonis, S. Sbyrakis, and J. Smeitink Application of a ketogenic diet in children with autistic behavior: pilot study J. Child Neurol. 18 2003 113 118
22. A. Fan, A. Berg, C. Bresee, L.H. Glassman, and M.H. Rapaport Allopurinol augmentation in the outpatient treatment of bipolar mania: a pilot study Bipolar Disord. 14 2012 206 210
23. A receptor downregulation in brains of subjects with autism J. Autism Dev. Disord. 39 2009 223 230
24. B.B. Fredholm Adenosine, an endogenous distress signal, modulates tissue damage and repair Cell Death Differ. 14 2007 1315 1323
25. B.B. Fredholm Notes on the history of caffeine use Handb. Exp. Pharmacol. 200 2011 1 9
26. B.B. Fredholm, K. Battig, J. Holmen, A. Nehlig, and E.E. Zvartau Actions of caffeine in the brain with special reference to factors that contribute to its widespread use Pharmacol. Rev. 51 1999 83 133
27. 2A receptor gene (ADORA2A) variants may increase autistic symptoms and anxiety in autism spectrum disorder Eur. Child Adolesc. Psychiatry 19 2010 67 74
28. Z.G. Gao, and K.A. Jacobson Emerging adenosine receptor agonists: an update Expert Opin. Emerg. Drugs 16 2011 597 602
29. A. Ghanizadeh Possible role of caffeine in autism spectrum disorders, a new testable hypothesis J. Food Sci. 75 2010 ix
30. T. Grandin Visual abilities and sensory differences in a person with autism Biol. Psychiatry 65 2009 15 16
31. 1 adenosine receptor-adenylate cyclase system in rat cerebral cortex J. Clin. Invest. 77 1986 222 227
32. R.H. Haas, M.A. Rice, D.A. Tauner, and T.A. Merritt Therapeutic effects of a ketogenic diet in Rett syndrome Am. J. Med. Genet. Suppl. 1 1986 225 246
33. A.M. Hassan, D.L. Keene, S.E. Whiting, P.J. Jacob, J.R. Champagne, and P. Humphreys Ketogenic diet in the treatment of refractory epilepsy in childhood Pediatr. Neurol. 21 1999 548 552
34. K. Herrick-Davis, S. Chippari, D. Luttinger, and S.J. Ward Evaluation of adenosine agonists as potential analgesics Eur. J. Pharmacol. 162 1989 365 369
35. I. Hertz-Picciotto, L. Croen, R. Hansen, C. Jones, J. van der Water, and I.N. Pessah The CHARGE study: an epidemiologic investigation of genetic and environmental factors contributing to autism Environ. Health Perspect. 114 2006 1119 1125
36. A receptor-mediated depolarization J. Neurosci. 32 2012 5321 5332
37. F.N. Jacka, P.J. Kremer, M. Berk, A.M. de Silva-Sanigorski, M. Moodie, E.R. Leslie, J.A. Pasco, and B.A. Swinburn A prospective study of diet quality and mental health in adolescents PLoS One 6 2011 e24805
38. F.N. Jacka, J.A. Pasco, A. Mykeltun, L.J. Williams, A.M. Hodge, S.L. O'Reilly, G.C. Nicholson, M.A. Kotowicz, and M. Berk Association of western and traditional diets with depression and anxiety in women Am. J. Psychiatry 167 2010 305 311
39. N. Jain, N. Kemp, O. Adeyemo, P. Buchanan, and T.W. Stone Anxiolytic activity of adenosine receptor activation in mice Br. J. Pharmacol. 116 1995 2127 2133
40. 1 mRNA in mouse brain: effect of long-term caffeine treatment Brain Res. 762 1997 153 164
41. 1 receptor Proc. Natl. Acad. Sci. U. S. A. 98 2001 9407 9412
42. ATP channels J. Neurosci. 30 2010 3886 3895
43. G.J. Keil, and G.E. DeLander Altered sensory behaviors in mice following manipulation of endogenous spinal adenosine neurotransmission Eur. J. Pharmacol. 312 1996 7 14
44. J.K. Kern, V.S. Miller, L. Cauller, R. Kendall, J. Mehta, and M. Dodd Effectiveness of N, N-dimethylglycine in autism and pervasive developmental disorder J. Child Neurol. 16 2001 169 173
45. J.K. Kern, M.H. Trivedi, C.R. Barver, B.D. Grannemann, A.A. Andrews, J.S. Savla, D.G. Johnson, J.A. Mehta, and J.L. Schroeder The pattern of sensory processing abnormalities in autism Autism 10 2006 480 494
46. P.R. Kerndt, J.L. Naughton, C.E. Driscoll, and D.A. Loxterkamp Fasting: the history, pathophysiology and complications West. J. Med. 137 1982 379 399
47. M.A. Kientz, and W. Dunn A comparison of the performance of children with and without autism on the sensory profile Am. J. Occup. Ther. 51 1996 530 537
48. B.H. King, and C. Lord Is schizophrenia on the autism spectrum? Brain Res. 1380 2011 34 41
49. K.S. Lam, M.G. Aman, and L.E. Arnold Neurochemical correlates of autistic disorder: a review of the literature Res. Dev. Disabil. 27 2006 254 289
50. P.J. Landrigan What causes autism? Exploring the environmental contribution Curr. Opin. Pediatr. 22 2010 219 225
51. D.R. Lara, M.G. Brunstein, E.S. Ghisolfi, M.I. Lobato, P. Belmonte-de-Abreu, and D.O. Souza Allopurinol augmentation for poorly responsive schizophrenia Int. Clin. Psychopharmacol. 16 2001 235 237
52. D.R. Lara, and D.O. Souza Schizophrenia: a purinergic hypothesis Med. Hypotheses 54 2000 157 166
53. L.A. LeBlanc, and J.M. Gillis Behavioral interventions for children with autism spectrum disorders Pediatr. Clin. North Am. 59 2012 147 164
54. S.R. Leekam, C. Nieto, S.J. Libby, J. Wing, and J. Gould Describing the sensory abnormalities of children and adults with autism J. Autism Dev. Disord. 37 2007 894 910
55. T. Li, G. Ren, T. Lusardi, A. Wilz, J.Q. Lan, T. Iwasato, S. Itohara, R.P. Simon, and D. Boison Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice J. Clin. Invest. 118 2008 571 582
56. W. Li, S. Dai, J. An, P. Li, X. Chen, R. Xiong, P. Liu, H. Wang, Y. Zhao, M. Zhu, X. Liu, P. Zhu, J.-F. Chen, and Y. Zhou Chronic but not acute treatment with caffeine attenuates traumatic brain injury in the mouse cortical impact model Neuroscience 151 2008 1198 1207
57. D. Lovatt, Q. Xu, W. Liu, T. Takano, N.A. Smith, J. Schnermann, K. Tieu, and M. Nedergaard Neuronal adenosine release, and not astrocytic ATP release, mediates feedback inhibition of excitatory activity Proc. Natl. Acad. Sci. U. S. A. 109 2012 6265 6270
58. 2 receptor binding in the rat brain: an autoradiographic study Synapse 9 1991 95 102
59. R. Machado-Vieira, J.C. Soares, D.R. Lara, D.A. Luckenbaugh, J.V. Busnello, G. Marca, A. Cunha, D.O. Souza, C.A. Zarate Jr.; and F. Kapczinski A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania J. Clin. Psychiatry 69 2008 1237 1245
60. J.G. Mantis, N.A. Centeno, M.T. Todorova, R. McGowan, and T.N. Seyfried Management of multifactorial idiopathic epilepsy in EL mice with caloric restriction and the ketogenic diet: role of glucose and ketone bodies Nutr. Metab. 1 2004 11
61. J.G. Mantis, C.L. Fritz, J. Marsh, S.C. Heinrichs, and T.N. Seyfried Improvement in motor and exploratory behavior in Rett syndrome mice with restricted ketogenic and standard diets Epilepsy Behav. 15 2009 133 141
62. C.C. Martinez, P.L. Pyzik, and E.H. Kossoff Discontinuing the ketogenic diet in seizure-free children: recurrence and risk factors Epilepsia 48 2007 187 190
63. S.A. Masino, M. Kawamura Jr.; L.M. Plotkin, J. Svedova, F.J. DiMario Jr.; and I.-E. Eigsti The relationship between the neuromodulator adenosine and behavioral symptoms of autism Neurosci. Lett. 500 2011 1 5
64. S.A. Masino, M. Kawamura Jr.; C.D. Wasser, L.T. Pomeroy, and D.N. Ruskin Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship between metabolism and brain activity Curr. Neuropharmacol. 7 2009 257 268
65. 1 receptors J. Clin. Invest. 121 2011 2679 2683
66. S.A. Masino, J. Svedova, J.L. Cote, M. Kawamura Jr.; and D.N. Ruskin Ketogenic Diet Reverses Autistic Behaviors in BTBR Mouse Model of Autism 2012 Society for Neuroscience San Diego, California
67. J.J. Meidenbauer, J.G. Mantis, and T.N. Seyfried The EL mouse: a natural model of autism and epilepsy Epilepsia 52 2011 347 357
68. E.G. Neal, H. Chaffe, R.H. Schwartz, M.S. Lawson, N. Edwards, G. Fitzsimmons, A. Whitney, and J.H. Cross The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial Lancet Neurol. 7 2008 500 506
69. J.J. Palop, J. Chin, E.D. Roberson, J. Wang, M.T. Thwin, N. Bien-Ly, J. Yoo, K.O. Ho, G.-Q. Yu, A. Kreitzer, S. Finkbeiner, J.L. Noebels, and L. Mucke Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease Neuron 55 2007 697 711
70. A.R.P. Paterson, and J.M. Oliver Nucleoside transport: II. Inhibition by p-nitrobenzylthioguanosine and related compounds Can. J. Biochem. 49 1971 271 274
71. E. Poleszak, and D. Manuta Influence of adenosine receptor agonists and antagonists on amphetamine-induced stereotypy in rats Pol. J. Pharmacol. 52 2000 423 429
72. T. Porkka-Heiskanen, and A.V. Kalinchuk Adenosine, energy metabolism and sleep homeostasis Sleep Med. Rev. 15 2011 123 135
73. D.J. Posey, K.A. Stigler, C.A. Erickson, and C.J. McDougle Antipsychotics in the treatment of autism J. Clin. Invest. 118 2008 6 14
74. A.E. Purcell, O.H. Jeon, A.W. Zimmerman, M.E. Blue, and J. Pevsner Postmortem brain abnormalities of the glutamate neurotransmitter system in autism Neurology 57 2001 1618 1628
75. 1 adenosine receptor expression in the chinchilla cochlea Hear. Res. 188 2004 47 56
76. J.A. Ribeiro, and A.M. Sebastião Caffeine and adenosine J. Alzheimers Dis. 20 Suppl. 1 2010 S3 S15
77. U. Rosenhall, V. Nordin, M. Sandström, G. Ahlsén, and C. Gillberg Autism and hearing loss J. Autism Dev. Disord. 29 1999 349 357
78. 1) receptors by caffeine treatment Neurosci. Lett. 103 1989 275 280
79. R.W. Rundles Metabolic effects of allopurinol and allo-xanthine Ann. Rheum. Dis. 25 6 Suppl. 1966 615 620
80. D.N. Ruskin, M. Kawamura Jr.; and S.A. Masino Reduced pain and inflammation in juvenile and adult rats fed a ketogenic diet PLoS One 4 2009 e8349
81. G. Rylander Psychosis and the punding and choreiform syndromes in addiction to central stimulant drugs Folia Psychiatr. Neurol. Neurochir. 75 1972 203 212
82. A. Sánchez-Villegas, L. Verberne, J. De Irala, M. Ruíz-Canela, E. Toledo, L. Serra-Majem, and M.A. Martínez- González Dietary fat intake and the risk of depression: the SUN Project PLoS One 6 2011 e16268
83. G. Sansa, C. Carlson, W. Doyle, H.L. Weiner, J. Bluvstein, W. Barr, and O. Devinsky Medically refractory epilepsy in autism Epilepsia 52 2011 1071 1075
84. 2A receptor in sleep promotion Eur. J. Pharmacol. 351 1998 155 162
85. 1 adenosine receptors Br. J. Pharmacol. 156 2009 163 172
86. M. Seidenberg, D.T. Pulsipher, and B. Hermann Association of epilepsy and comorbid conditions Future Neurol. 4 2009 663 668
87. H.-Y. Shen, P. Singer, N. Lytle, C. Wei, J.-Q. Lan, R.L. Williams-Karnesky, J.-F. Chen, B.K. Yee, and D. Boison Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia in mice J. Clin. Invest. 122 2012 2567 2577
88. B. Siegel, E. Ihle, E. Marco, and R. Hendren Update on autism: issues in treatment and comorbidity Psychiatr. Times 27 2010 33 39
89. S.L. Stella Jr.; W.D. Hu, and N.C. Brecha Adenosine suppresses exocytosis from cone terminals of the salamander retina NeuroReport 20 2010 923 929
90. 1 receptor J. Sleep Res. 12 2003 283 290
91. Y. Tanimura, S. Vaziri, and M.H. Lewis Indirect basal ganglia pathway mediation of repetitive behavior: attenuation by adenosine receptor agonists Behav. Brain Res. 210 2010 116 122
92. M.T. Todorova, P. Tandon, R.A. Madore, C.E. Stafstrom, and T.N. Seyfried The ketogenic diet inhibits epileptogenesis in EL mice: a genetic model for idiopathic epilepsy Epilepsia 41 2000 933 940
93. M. Togha, S. Akhondzadeh, M. Motamedi, B. Ahmadi, and S. Razeghi Allopurinol as adjunctive therapy in intractable epilepsy: a double-blind and placebo-controlled trial Arch. Med. Res. 38 2007 313 316
94. S.Y. Tse, and E.T. Wei Inhibition of the shake response in rats by adenosine and 2-chloroadenosine Psychopharmacology 90 1986 322 326
95. 1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis J. Neurosci. 24 2004 1521 1529
96. R. Tuchman, and I. Rapin Epilepsy in autism Lancet Neurol. 1 2002 352 358
97. E.P. Vining, J.M. Freeman, K. Ballaban-Gil, C.S. Camfield, P.R. Camfield, G.L. Holmes, S. Shinnar, R. Shuman, E. Trevathan, and J.W. Wheless A multicenter study of the efficacy of the ketogenic diet Arch. Neurol. 55 1998 1433 1437
98. S.M. Vlajkovic, S. Abi, C.J. Wang, and G.D. Housley Differential distribution of adenosine receptors in rat cochlea Cell Tissue Res. 328 2007 461 471
99. M. Weiser, A.A. Gershon, K. Rubinstein, C. Petcu, M. Ladea, D. Sima, D. Podea, R.S. Keefe, and J.M. Davis A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder Schizophr. Res. 138 2012 35 38
100. J.W. Wheless History of the ketogenic diet Epilepsia 49 Suppl. 8 2008 3 5
101. S.W. White, D. Oswald, T. Ollendick, and L. Scahill Anxiety in children and adolescents with autism spectrum disorders Clin. Psychol. Rev. 29 2009 216 229
102. R.M. Wilder The effects of ketonemia on the course of epilepsy Mayo Clin. Bull. 2 1921 307
103. R.M. Wilder High fat diets in epilepsy Mayo Clin. Bull. 2 1921 308
104. H.J. Yoo, S.K. Lee, M. Park, I.H. Cho, S.H. Hyun, J.C. Lee, S.Y. Yang, and S.A. Kim Family- and population-based association studies of monoamine oxidase A and autism spectrum disorders in Korean Neurosci. Res. 63 2009 172 176
105. P.G. Zagnoni, A. Bianchi, P. Zolo, R. Canger, C. Cornaggia, P. D'Alessandro, P. DeMarco, F. Pisani, M. Gianelli, and L. Verze Allopurinol as add-on therapy in refractory epilepsy: a double-blind placebo-controlled randomized study Epilepsia 35 1994 107 112
106. 1 receptors J. Neurosci. 31 2011 6221 6234